Jefferies Group LLC Reaffirms Buy Rating for Integra LifeSciences Holdings Corporation (IART)

Jefferies Group LLC reissued their buy rating on shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) in a research report released on Sunday morning.

A number of other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Integra LifeSciences Holdings Corporation from a hold rating to a sell rating in a research report on Wednesday, June 28th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $65.00 target price on shares of Integra LifeSciences Holdings Corporation in a research report on Monday, July 10th. BidaskClub downgraded shares of Integra LifeSciences Holdings Corporation from a buy rating to a hold rating in a research report on Monday, July 24th. Oppenheimer Holdings, Inc. set a $54.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the stock a buy rating in a research report on Monday, May 15th. Finally, ValuEngine downgraded shares of Integra LifeSciences Holdings Corporation from a buy rating to a hold rating in a research report on Tuesday, May 23rd. Five research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Integra LifeSciences Holdings Corporation has an average rating of Buy and a consensus price target of $53.54.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 53.63 on Friday. The firm has a 50 day moving average of $50.45 and a 200-day moving average of $48.18. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of 65.40 and a beta of 0.73. Integra LifeSciences Holdings Corporation has a 1-year low of $37.71 and a 1-year high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.45. The firm had revenue of $282.16 million for the quarter, compared to the consensus estimate of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The company’s revenue was up 13.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.40 EPS. On average, equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Jefferies Group LLC Reaffirms Buy Rating for Integra LifeSciences Holdings Corporation (IART)” was published by Markets Daily and is owned by of Markets Daily. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.themarketsdaily.com/2017/09/13/jefferies-group-llc-reaffirms-buy-rating-for-integra-lifesciences-holdings-corporation-iart.html.

In other news, Director Donald E. Morel, Jr. acquired 2,500 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The shares were bought at an average cost of $49.29 per share, with a total value of $123,225.00. Following the transaction, the director now owns 29,612 shares of the company’s stock, valued at approximately $1,459,575.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were purchased at an average cost of $49.25 per share, for a total transaction of $492,500.00. Following the completion of the transaction, the director now directly owns 29,612 shares in the company, valued at approximately $1,458,391. The disclosure for this purchase can be found here. Insiders have purchased a total of 17,550 shares of company stock worth $864,842 over the last three months. 21.50% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. LS Investment Advisors LLC lifted its stake in Integra LifeSciences Holdings Corporation by 4.6% during the 2nd quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock valued at $138,000 after acquiring an additional 111 shares during the period. Pinebridge Investments L.P. lifted its stake in Integra LifeSciences Holdings Corporation by 2.2% during the 2nd quarter. Pinebridge Investments L.P. now owns 7,971 shares of the life sciences company’s stock valued at $435,000 after acquiring an additional 174 shares during the period. Ameritas Investment Partners Inc. lifted its stake in Integra LifeSciences Holdings Corporation by 3.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,409 shares of the life sciences company’s stock valued at $295,000 after acquiring an additional 187 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Integra LifeSciences Holdings Corporation by 8.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after acquiring an additional 218 shares during the period. Finally, Louisiana State Employees Retirement System lifted its stake in Integra LifeSciences Holdings Corporation by 1.2% during the 2nd quarter. Louisiana State Employees Retirement System now owns 24,600 shares of the life sciences company’s stock valued at $1,341,000 after acquiring an additional 300 shares during the period. 85.28% of the stock is currently owned by institutional investors.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply